Growth Hormone Deficiency Market Report 2026

Growth Hormone Deficiency Market Overview

• Growth Hormone Deficiency market size has reached to $4.3 billion in 2025 • Expected to grow to $5.67 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: The Genetic Disorder Prevalence Driving The Market Growth • Market Trend: Skytrofa Launches As Once-weekly Treatment For Growth Hormone Deficiency • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Growth Hormone Deficiency Market?

Growth hormone deficiency (GHD) is a medical condition in which the pituitary gland does not produce enough growth hormone (GH). This deficiency leads to stunted growth and development in children and various metabolic issues in adults. Growth hormone deficiency can be congenital (present at birth) or acquired due to injury, tumors, infections, or other medical conditions affecting the pituitary gland. The main types of growth hormone deficiency are pediatric growth hormone deficiency and adult growth hormone deficiency. Pediatric growth hormone deficiency focuses on children with inadequate growth hormone production, resulting in stunted growth and delayed development. Treatments involved are pharmacological therapy, recombinant human growth hormone, human pituitary gland extracts, and surgery. The various routes of administration include intravenous, intramuscular, and others. They are distributed through several channels, such as hospital pharmacy, online pharmacy, and retail pharmacy, and are used by multiple end users, including hospitals, home care, specialty clinics, and others.

What Is The Growth Hormone Deficiency Market Growth Forecast?

The growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $5.67 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing demand for personalized hormone therapies, rising investments in endocrine research, expansion of home-based treatment administration, growing use of digital health monitoring tools, increasing focus on long-acting growth hormone formulations. Major trends in the forecast period include increasing adoption of recombinant growth hormone therapies, rising use of personalized treatment approaches, growing focus on early diagnosis of hormonal disorders, expansion of long-term hormone replacement programs, enhanced monitoring of treatment outcomes.

Global Growth Hormone Deficiency Market Segmentation

1) By Type: Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency 2) By Treatment: Pharmacological Therapy, Recombinant Human Growth Hormone 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy 4) By End User: Hospitals, Homecare, Specialty Clinics Subsegments: 1) By Pediatric Growth Hormone Deficiency: Idiopathic Growth Hormone Deficiency, Genetic Growth Hormone Deficiency, Acquired Growth Hormone Deficiency 2) By Adult Growth Hormone Deficiency: Primary Growth Hormone Deficiency, Secondary Growth Hormone Deficiency

What Is The Driver Of The Growth Hormone Deficiency Market?

The growing prevalence of genetic disorders is expected to propel the growth of the growth hormone deficiency market going forward. Genetic disorders refer to medical conditions caused by abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. The prevalence of genetic disorders is due to advancements in diagnostic technology, increased awareness, rising maternal age, environmental factors causing mutations, population growth, and improved survival rates for affected individuals. Growth hormone deficiency is used to manage growth-related complications in certain genetic conditions. For instance, in October 2024, according to Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, in 2022, around 11,148 cystic fibrosis (a genetic disorder) patients were registered, and this number grew to 11,318 in 2023, reflecting a 1.5% increase in patient registrations year over year. Therefore, the growing prevalence of genetic disorders drives the growth of the growth hormone deficiency industry.

Key Players In The Global Growth Hormone Deficiency Market

Major companies operating in the growth hormone deficiency market are Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck KGaA, Ipsen, Ascendis Pharma A/S, Opko Health Inc., Genentech Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Ferring Pharmaceuticals, JCR Pharmaceuticals, LG Chem, BioPartners, GeneScience Pharmaceuticals, SciClone Pharmaceuticals, AnkeBio, Versartis, Aeterna Zentaris

Global Growth Hormone Deficiency Market Trends and Insights

Major companies operating in the growth hormone deficiency market are focusing on developing innovative products, such as unmodified somatropin, for daily pediatric growth hormone deficiency (GHD) treatments. Unmodified somatropin refers to the same growth hormone used in daily pediatric growth hormone deficiency treatments but delivered in a once-weekly dosage with Skytrofa. For instance, in September 2023, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched the SKYTROFA (lonapegsomatropin) for the once-weekly treatment of pediatric growth hormone deficiency (GHD). This innovative therapy offers enhanced convenience, improved adherence, and potentially better treatment outcomes than traditional daily growth hormone therapies. It is the first and only FDA-approved once-weekly treatment for pediatric GHD, positioning it as a groundbreaking advancement in endocrinology and pediatric care.

What Are Latest Mergers And Acquisitions In The Growth Hormone Deficiency Market?

In October 2024, Double Point Ventures LLC (DPV), a U.S.-based investment firm, acquired Lumos Pharma for an undisclosed amount. With this acquisition, the aim is to advance the development and potential commercialization of Lumos Pharma’s oral GH-secretagogue for pediatric growth hormone deficiency and to strengthen DPV’s position in the rare endocrine disorders space. Lumos Pharma is a U.S.-based clinical-stage biopharmaceutical company developing therapies for pediatric growth hormone deficiency.

Regional Outlook

North America was the largest region in the growth hormone deficiency market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Growth Hormone Deficiency Market?

The growth hormone deficiency market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and specialized services. The market value includes the value of related goods sold by the service provider or included within the service offering. The growth hormone deficiency market consists of sales of recombinant human growth hormones, long-acting growth hormones and combination therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Growth Hormone Deficiency Market Report 2026?

The growth hormone deficiency market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the growth hormone deficiency industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.